STKL Stock Recent News
STKL LATEST HEADLINES
SunOpta continues to deliver strong revenue and profit growth, driven by robust demand and a favorable product mix across plant-based beverages and snacks. Despite tariff headwinds and some pricing pressure, management's proactive price adjustments and cost controls support margin resilience and an improved outlook. Valuation remains attractive compared to peers, with 2027 targets implying 13%-18% annualized upside if management's growth projections are met.
SunOpta (STKL) could produce exceptional returns because of its solid growth attributes.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, SunOpta (STKL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
The average of price targets set by Wall Street analysts indicates a potential upside of 60.3% in SunOpta (STKL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PTON, SFM, STKL, and BODI are tapping into an $11T wellness market, boosted by tech, nutrition, and holistic health trends.
SunOpta (STKL) could produce exceptional returns because of its solid growth attributes.
SunOpta Inc. (NASDAQ:STKL ) Q2 2025 Earnings Conference Call August 6, 2025 5:30 PM ET Company Participants Brian W. Kocher - CEO & Director Greg Gaba - Chief Financial Officer Conference Call Participants Andrew Strelzik - BMO Capital Markets Equity Research James Ronald Salera - Stephens Inc., Research Division John Joseph Baumgartner - Mizuho Securities USA LLC, Research Division Jon Robert Andersen - William Blair & Company L.L.C.
SunOpta (STKL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago.
MINNEAPOLIS--(BUSINESS WIRE)--SUNOPTA ANNOUNCES SECOND QUARTER FISCAL 2025 FINANCIAL RESULTS.
CPRX, STKL, GAMB and ORN are gaining attention as rising cash flows signal strength, flexibility and growth potential.